127 related articles for article (PubMed ID: 21971288)
1. Neuroblastoma therapy: what is in the pipeline?
Verissimo CS; Molenaar JJ; Fitzsimons CP; Vreugdenhil E
Endocr Relat Cancer; 2011 Dec; 18(6):R213-31. PubMed ID: 21971288
[TBL] [Abstract][Full Text] [Related]
2. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy.
Morgenstern DA; Baruchel S; Irwin MS
J Pediatr Hematol Oncol; 2013 Jul; 35(5):337-47. PubMed ID: 23703550
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
[TBL] [Abstract][Full Text] [Related]
5. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
Wiedenmann B; Pavel M; Kos-Kudla B
Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
[TBL] [Abstract][Full Text] [Related]
6. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges.
Pollack IF
J Neurosurg Pediatr; 2011 Aug; 8(2):135-48. PubMed ID: 21806354
[TBL] [Abstract][Full Text] [Related]
8. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.
Poremba C; Hero B; Goertz HG; Scheel C; Wai D; Schaefer KL; Christiansen H; Berthold F; Juergens H; Boecker W; Dockhorn-Dworniczak B
Klin Padiatr; 2001; 213(4):186-90. PubMed ID: 11528552
[TBL] [Abstract][Full Text] [Related]
9. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.
Øra I; Eggert A
Semin Cancer Biol; 2011 Oct; 21(4):217-28. PubMed ID: 21798350
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic targets for the treatment of high-risk neuroblastoma.
Wagner LM; Danks MK
J Cell Biochem; 2009 May; 107(1):46-57. PubMed ID: 19277986
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
[TBL] [Abstract][Full Text] [Related]
12. [Natural human IgM-antibodies in neuroblastoma therapy: preliminary findings of a phase I/II clinical trial].
Schmitt C; David K; Hiller J; Schrum J; Bredehorst R; Vogel CW; Löliger C; Erttmann R
Klin Padiatr; 1999; 211(4):314-8. PubMed ID: 10472569
[TBL] [Abstract][Full Text] [Related]
13. Prospects for therapeutic inhibition of neuroblastoma angiogenesis.
Shusterman S; Maris JM
Cancer Lett; 2005 Oct; 228(1-2):171-9. PubMed ID: 15927358
[TBL] [Abstract][Full Text] [Related]
14. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
Gustafson WC; Matthay KK
Expert Rev Neurother; 2011 Oct; 11(10):1411-23. PubMed ID: 21955198
[TBL] [Abstract][Full Text] [Related]
15. Chronic neuroblastoma.
Kushner BH; Kramer K; Cheung NK
Cancer; 2002 Sep; 95(6):1366-75. PubMed ID: 12216106
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.
Welch C; Chen Y; Stallings RL
Oncogene; 2007 Jul; 26(34):5017-22. PubMed ID: 17297439
[TBL] [Abstract][Full Text] [Related]
17. Proteomic approaches in neuroblastoma: a complementary clinical platform for the future.
Kumar HR; Zhong X; Rescorla FJ; Hickey RJ; Malkas LH; Sandoval JA
Expert Rev Proteomics; 2009 Aug; 6(4):387-94. PubMed ID: 19681674
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth.
Streck CJ; Zhang Y; Zhou J; Ng C; Nathwani AC; Davidoff AM
J Pediatr Surg; 2005 Jan; 40(1):236-43. PubMed ID: 15868591
[TBL] [Abstract][Full Text] [Related]
19. All-trans retinoic acid arrests neuroblastoma cells in a dormant state. Subsequent nerve growth factor/brain-derived neurotrophic factor treatment adds modest benefit.
Cernaianu G; Brandmaier P; Scholz G; Ackermann OP; Alt R; Rothe K; Cross M; Witzigmann H; Tröbs RB
J Pediatr Surg; 2008 Jul; 43(7):1284-94. PubMed ID: 18639684
[TBL] [Abstract][Full Text] [Related]
20. Editorial review: targets for glioma treatment: from bench to bedside.
Sanson M
Curr Opin Oncol; 2008 Nov; 20(6):650-1. PubMed ID: 18841046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
